Your session is about to expire
← Back to Search
Atypical Antidepressant
Optimizing Outcomes of Treatment-Resistant Depression in Older Adults (OPTIMUM Trial)
Phase 4
Waitlist Available
Led By Eric Lenze, MD
Research Sponsored by Washington University School of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 6 months, 24 months
Awards & highlights
Drug Has Already Been Approved
Pivotal Trial
No Placebo-Only Group
Summary
The purpose of this research study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD).
Eligible Conditions
- Depression
- Geriatric Depression
- Major Depressive Disorder
- Late-Life Depression
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, 6 months, 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 6 months, 24 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of Participants With Remission From Depression
Psychological Well-Being
Serious Adverse Events
Secondary study objectives
Change in episodic memory
Change in executive function
Change in executive-control and cortico-limbic circuitry
+3 moreAwards & Highlights
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
5Treatment groups
Experimental Treatment
Group I: Switch to NortriptylineExperimental Treatment1 Intervention
Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml.
Group II: Switch to BupropionExperimental Treatment1 Intervention
Taper from current antidepressant therapy. Start bupropion once-daily extended, titrated from 150-300 mg daily based on symptom severity and side effects.
Group III: Lithium AugmentationExperimental Treatment1 Intervention
Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
Group IV: Bupropion AugmentationExperimental Treatment1 Intervention
Augment current antidepressant treatment with bupropion once-daily extended release, titrated from 150-300 mg daily based on symptom severity and side effects.
Group V: Aripiprazole AugmentationExperimental Treatment1 Intervention
Augment current antidepressant treatment with aripiprazole (tablets), titrated from 2-15 mg daily based on symptom severity and side effects.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bupropion Augmentation
2017
Completed Phase 4
~830
Switch to bupropion
2017
Completed Phase 4
~830
Aripiprazole Augmentation
2017
Completed Phase 4
~830
Lithium Augmentation
2017
Completed Phase 4
~830
Switch to nortriptyline
2017
Completed Phase 4
~830
Find a Location
Who is running the clinical trial?
Washington University School of MedicineLead Sponsor
2,000 Previous Clinical Trials
2,343,568 Total Patients Enrolled
Patient-Centered Outcomes Research InstituteOTHER
580 Previous Clinical Trials
27,104,517 Total Patients Enrolled
National Institute of Mental Health (NIMH)NIH
2,936 Previous Clinical Trials
2,750,899 Total Patients Enrolled
Eric Lenze, MDPrincipal Investigator - Washington University School of Medicine
Barnes-Jewish Hospital
Washington University School Of Medicine (Medical School)
University Hlth Ctr Of Pittsburgh (Residency)
9 Previous Clinical Trials
2,605 Total Patients Enrolled